デフォルト表紙
市場調査レポート
商品コード
1020442

ペニシリン薬市場-成長、動向、COVID-19の影響、および予測(2021~2026年)

Penicillin Drug Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

出版日: | 発行: Mordor Intelligence Pvt Ltd | ページ情報: 英文 115 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=115.03円
ペニシリン薬市場-成長、動向、COVID-19の影響、および予測(2021~2026年)
出版日: 2021年07月01日
発行: Mordor Intelligence Pvt Ltd
ページ情報: 英文 115 Pages
納期: 2-3営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

ペニシリン薬の市場規模は、予測期間にわたって、5.2%の推定CAGRで拡大すると予測されています。

世界的に、COVID-19は主要な公衆衛生問題になっています。COVID-19症例の約15%が重症であると推定されており、そのうち少なくとも5%の人が重篤な感染症を患い人工呼吸器を必要としています。VA Schad(2021)の記事によると、COVID-19で入院した患者の最初の報告では、10%から33%が細菌性肺炎を発症していることが示されています。入院とICU挿管は、ブドウ球菌、緑膿菌、クレブシエラなどの病原体にへの感染において重要な要因であることが観察されています。したがって、Covid-19はペニシリン薬市場に大きな影響を与えるでしょう。

効果的で新しい抗生物質の必要性と相まって、細菌感染の有病率の上昇は、高度な抗生物質の需要を推進しています。医師は、肺炎やその他の呼吸器感染症、猩紅熱、耳、皮膚、歯茎、口、喉の感染症などのさまざまな感染症の治療にペニシリンまたはアモキシシリンを処方する場合があります。それらはより安全で安価であり、広範囲の細菌にうまく作用するため、他の薬剤よりも好まれます。ユニセフによると、世界では10万人の子供あたり1,400例以上、または71人の子供あたり1例が毎年発生しており、最も発生率が高いのは南アジア(10万人の子供あたり2,500例)と西アフリカおよび中央アフリカ(10万人あたり1,620例)です。細菌感染によって引き起こされる別の深刻な状態は、「感染に対する調節不全の宿主反応によって引き起こされる生命を脅かす臓器機能不全」として定義される敗血症です。敗血症の疫学と負担に関する世界保健機関(WHO)の報告(2020年)では、ある年に敗血症は4,900万人に影響を及ぼし、世界中で約1,100万人の潜在的に回避可能な死亡につながっています。上記のすべての事実を考慮して、ペニシリン薬市場は予測期間にわたって大幅な成長を遂げると予測されています。

当レポートでは、ペニシリン薬市場について調査し、市場の概要とともに、ソース別、クラス別、投与ルート別、活動スペクトル別、流通チャネル別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場概要
  • 市場の推進力
    • 感染症の負担の増加
    • 製薬業界における研究開発活動の増加
    • ジェネリック医薬品の需要と開発の増加
  • 市場の抑制要因
    • 抗菌剤に対する耐性の増加
    • 新しいクラスの多様な抗菌剤との発見と激しい競合
    • 厳格な規制の枠組み
  • ポーターのファイブフォース分析

第5章 市場セグメンテーション

  • ソース別
    • 自然
    • 生合成
    • 半合成
  • クラス別
    • アミノペニシリン
    • 緑膿菌ペニシリン
    • ベータラクタマーゼ阻害剤
    • ペニシリナーゼ耐性ペニシリン
  • 投与ルート別
    • 経口
    • 非経口
  • 活動スペクトル別
    • 狭域スペクトル
    • 広域スペクトラム
    • 中間スペクトル
    • 拡張スペクトル
  • 流通チャネル別
    • 病院薬局
    • 小売薬局
    • オンライン薬局
    • その他
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋
    • 中東とアフリカ
    • 南米

第6章 競合情勢

  • 企業プロファイル
    • Pfizer, Inc.
    • Novartis AG
    • Sanofi SA
    • Astellas Pharma, Inc.
    • GlaxoSmithKline plc
    • Merck Co. and Inc.
    • FUJIFILM Toyama Chemical Co., Ltd.
    • Sun Pharmaceutical Industries
    • Lupin Limited
    • Cipla Limited
    • Bayer AG
    • F. Hoffmann-La Roche AG
    • Daiichi Sankyo Company Ltd.

第7章 市場機会と動向

目次
Product Code: 72174

The Penicillin Drug market studied is expected to grow with an estimated CAGR of 5.2%, over the forecast period.

Globally, COVID-19 has become a major public health problem. It is estimated that around 15% of COVID-19 cases are severe, and among them, at least 5% of people have critical infections and need a ventilator. According to an article by V.A. Schad (2021), initial reports of patients hospitalized with COVID-19 indicate that 10% to 33% develop bacterial pneumonia. It is observed that hospitalization and ICU intubation are more important factors in conferring infection to pathogens such as Staphylococcus. aureus, Pseudomonas aeruginosa, and Klebsiella spp. Thus Covid-19 will have a major impact on the Penicillin Drug market.

The rising prevalence of bacterial infections, coupled with the need for effective and newer antibiotics, is driving the demand for advanced antibiotics. Doctors often prescribe penicillin or amoxicillin for the treatment of various infections such as pneumonia and other respiratory tract infections, scarlet fever, and ear, skin, gum, mouth, and throat infections. They are preferred over other drugs because they're safer, inexpensive, and they work well on a broad range of bacteria. According to UNICEF, globally there are over 1,400 cases of pneumonia per 100,000 children, or 1 case per 71 children every year, with the greatest incidence occurring in South Asia (2,500 cases per 100,000 children) and West and Central Africa (1,620 cases per 100,000 children). Another serious condition caused because of bacterial infection is Sepsis which is defined as "life-threatening organ dysfunction caused by a dysregulated host response to infection". A report by the World Health Organization (WHO) on the epidemiology and burden of sepsis (2020), in a given year, sepsis had affected 49 million individuals and was related to approximately 11 million potentially avoidable deaths worldwide. In view of all the mentioned facts, the Penicillin Drug Market is expected to witness significant growth over the forecast period.

However rising number of multidrug-resistant (MDR) pathogens is a major barrier in the development of effective treatment for infectious disease. According to researchers such as Richard Bax, the new technologies of bacterial genomics and high-throughput screening are not appropriate ways to discover new classes of diverse, low molecular weight antibacterials that are active in vitro, especially against MDR pathogens. More efforts are required in terms of technological developments to address the upcoming challenges of MDR and model a penicillin class drug that can be effective against MDR pathogens. Factors such as these will hinder the growth dynamics of penicillin drug market if not addressed.

Key Market Trends

The Extended Spectrum Penicillin Segment Is Expected To Grow Faster And Dominate The Market Over The Forecast Period

Extended Spectrum Penicillins is anticipated to hold the major share of revenue in the Spectrum of Activity segment over the forecast period. The extended-spectrum penicillins consist of drugs such as carbenicilllin, mezlocillin, piperacillin, and ticarcillin. These are groups of semi-synthetic penicillin antibiotics that, because of their chemical structure, have a wider spectrum of activity than natural penicillins. They are more active against Gram-negative bacteria because they are more resistant to inactivation by extended-spectrum B-lactamases (ESBLs) produced by these Gram-negative bacteria. Infections caused by resistant gram-negative bacteria are becoming increasingly prevalent. They are difficult to treat and are associated with high rates of morbidity and mortality.

Monotherapy with penicillin drugs is commonly used in patients with mild to moderate pneumonia. The increasing incidence of infectious diseases is predicted to accelerate the market for these penicillin drugs. As per an article by H. Regunath (2020) titled "Community-Acquired Pneumonia", the estimated worldwide incidence of community-acquired pneumonia varies between 1.5 to 14 cases per 1000 person-years. Additionally, despite several developments in fighting childhood illnesses, infectious diseases remain a leading cause of death for children under the age of 5, particularly in sub-Saharan Africa and Southern Asia. According to the UNICEF report of 2019 on "Levels and Trends in Child Mortality", it was observed that for children below age 5, Pneumonia (15 percent), diarrhea (8 percent), and malaria (5 percent) remain among the leading causes of death globally. This shows that infectious diseases remain a leading cause of death among children under age 5 with most deaths due to Pneumonia.

Additionally, few players are trying to address the need for a new class of antibiotics required to treat emerging resistance bacteria. For instance, Qpex Biopharma is developing an ultra-broad-spectrum oral beta-lactamase inhibitor (QPX7728) for use in combination with beta-lactam antibiotics for drug-resistant gram-negative bacterial infections. ​ On the basis of the above-mentioned factors, it is expected that the penicillin drug segment will augment over the forecast period.

North America Dominates the Market and Expected to do Same in the Forecast Period

North America holds the major market share in the Penicillin Drug market and is expected to dominate the overall market throughout the forecast period. Penicillin is a widely used antibiotic prescribed to treat infectious diseases caused by bacteria such as staphylococci and streptococci. As per the Centers for Disease Control and Prevention, as many as 120,000 people suffered from bloodstream Staphylococcus aureus infections in the United States in 2017, and nearly 20,000 died, according to the report by CDC. Another highly infectious disease pneumonia caused by viruses, bacteria, or fungi is also on the rise in the region.

The major driver for this trend is the increasing burden of infectious diseases​, which leads to an increase in the use of various antibiotics. Age also has a significant impact on the risk of contracting any infectious disease, with both pediatric and geriatric populations with higher rates of getting infected. According to an article by Forest W. Arnold (2020) titled "Older Adults Hospitalized for Pneumonia in the United States: Incidence, Epidemiology, and Outcomes", where the author estimated the burden of community-acquired pneumonia (CAP) in the older adult population of the United States found that the incidence of CAP was about 2100 per 100,000 population. The number corresponds to 970,000 older adults in the United States hospitalized per year with CAP. The study reported 30-day mortalities of 14% for ward patients and 33% for ICU patients, thus showing significant differences and high mortality. According to American thoracic Society (2019), there are 120 million episodes of pneumonia per year in children under 5, over 10% of which progress to severe episodes.

Market players in the country are extensively focusing on the development of novel drugs to treat infectious disease, and they are also adopting various strategies to develop new class of drugs. Thus, this is likely to drive the market in the country. For instance, in August 2019, the US Food and Drug Administration approved xenleta (lefamulin) to treat adults with community-acquired bacterial pneumonia. Recently in June 2021, the FDA has approved omadacycline (Paratek Pharmaceuticals), an oral-only dosing regimen, for the treatment of community-acquired bacterial pneumonia. Owing to these recent developments and other above mentioned factors the penicillin drug market is expected to get a boost in the region.

Competitive Landscape

The Penicillin Drug market is highly competitive with several players across the globe. In terms of market share, few of the major players currently dominate the market. With the increase in research and development activity, many regional players are expected to contribute to the penicillin drug market over the forecast period. Some of the major players of the market are Pfizer, Inc., Novartis AG, Sanofi S.A., Astellas Pharma, Inc., GlaxoSmithKline plc, Merck Co. and Inc., Fujifilm Toyama Chemical Co. Ltd., Sun Pharmaceutical Industries, Lupin Limited, Cipla Limited, Bayer AG, F. Hoffmann-La Roche AG, Daiichi Sankyo Company Ltd., and others.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Burden of Infectious Diseases​
    • 4.2.2 Increasing R and D Activities in the Pharmaceutical Industry
    • 4.2.3 Increasing Demand and Development of Generic Drugs
  • 4.3 Market Restraints
    • 4.3.1 Increasing Resistance to Anti-microbials
    • 4.3.2 Discovery and Fierce Competition With New Class of Diverse Antibacterials
    • 4.3.3 Stringent Regulatory Framework
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Source
    • 5.1.1 Natural
    • 5.1.2 Biosynthesis
    • 5.1.3 Semisynthesis
  • 5.2 By Class
    • 5.2.1 Aminopenicillin
    • 5.2.2 Antipseudomonal Penicillin
    • 5.2.3 Beta-lactamase Inhibitor
    • 5.2.4 Penicillinase-resistant Penicillin
  • 5.3 By Route of Administration
    • 5.3.1 Oral
    • 5.3.2 Parenteral
  • 5.4 By Spectrum of activity
    • 5.4.1 Narrow Spectrum
    • 5.4.2 Broad Spectrum
    • 5.4.3 Intermediate Spectrum
    • 5.4.4 Extended Spectrum
  • 5.5 By Distribution Channel
    • 5.5.1 Hospital Pharmacies
    • 5.5.2 Retail Pharmacies
    • 5.5.3 Online Pharmacies
    • 5.5.4 Other Distribution Channels
  • 5.6 Geography
    • 5.6.1 North America
      • 5.6.1.1 United States
      • 5.6.1.2 Canada
      • 5.6.1.3 Mexico
    • 5.6.2 Europe
      • 5.6.2.1 Germany
      • 5.6.2.2 United Kingdom
      • 5.6.2.3 France
      • 5.6.2.4 Italy
      • 5.6.2.5 Spain
      • 5.6.2.6 Rest of Europe
    • 5.6.3 Asia-Pacific
      • 5.6.3.1 China
      • 5.6.3.2 Japan
      • 5.6.3.3 India
      • 5.6.3.4 Australia
      • 5.6.3.5 South Korea
      • 5.6.3.6 Rest of Asia-Pacific
    • 5.6.4 Middle East and Africa
      • 5.6.4.1 GCC
      • 5.6.4.2 South Africa
      • 5.6.4.3 Rest of Middle East and Africa
    • 5.6.5 South America
      • 5.6.5.1 Brazil
      • 5.6.5.2 Argentina
      • 5.6.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Pfizer, Inc.
    • 6.1.2 Novartis AG
    • 6.1.3 Sanofi S.A.
    • 6.1.4 Astellas Pharma, Inc.
    • 6.1.5 GlaxoSmithKline plc
    • 6.1.6 Merck Co. and Inc.
    • 6.1.7 FUJIFILM Toyama Chemical Co., Ltd.
    • 6.1.8 Sun Pharmaceutical Industries
    • 6.1.9 Lupin Limited
    • 6.1.10 Cipla Limited
    • 6.1.11 Bayer AG
    • 6.1.12 F. Hoffmann-La Roche AG
    • 6.1.13 Daiichi Sankyo Company Ltd.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS